Cardiovascular Pharmacotherapeutics: Abridged and Updated provides current, on-the-spot information on how to use every approved cardiovascular drug in adults and children, and the scientific rationale for their clinical use. A clinical distillation of the editors’ comprehensive and highly respected Cardiovascular Pharmacotherapeutics 3rd edition textbook, this treatment-centered abridgement features:

• Indications, contraindications, dosage, side effects, pharmacokinetics, and adverse reactions for all approved cardiovascular drugs, including the newest therapeutic agents to become available

• Rationales and usage guidelines for therapeutic strategies

• Abundant tables and charts that summarize important clinical choices

• Handy appendices that review approved uses of cardiovascular agents and their pharmacologic characteristics

• Considerations for managing patients on multi-drug regimens

• Details on drug-drug interactions

• Updated information on alternative medicine approaches to cardiovascular disease

NEW FEATURES

New with the third edition is an accompanying website, www.cvpct3.com, which highlights advances in cardiovascular drug therapy. Along with providing periodic updates to each chapter, including links to the latest studies, the site reviews cardiovascular drugs newly approved by the FDA for clinical use as well as drugs under investigation. Readers are invited to use the website to communicate directly with the book’s authors regarding topics related to cardiovascular drug use.

---

This book is an abridged and updated version of Cardiovascular Pharmacotherapeutics. Compared to the hardcover 3rd edition, it excludes part 1 (with the exception of the first chapter), includes all of part 2, excludes part 3 (with the exception of chapters 30 and 31), and includes appendices 1 and 2; appendices 3-8 are excluded.

This book is an abridged and updated version of Cardiovascular Pharmacotherapeutics. Compared to the hardcover 3rd edition, it excludes part 1 (with the exception of the first chapter), includes all of part 2, excludes part 3 (with the exception of chapters 30 and 31), and includes appendices 1 and 2; appendices 3-8 are excluded.

---

Part 1: Introduction

1. Basic Principles of Clinical Pharmacology Relevant to Cardiology
William H. Frishman


Part 2: Drug Classes

5. Alpha- and Beta-Adrenergic Blocking Drugs
William H. Frishman

6. Central and Peripheral Sympatholytics
Lawrence R. Krakoff and William H. Frishman

7. Cholinergic and Anticholinergic Drugs
B. Robert Meyer and William H. Frishman

8. Calcium Channel Blockers
William H. Frishman and Domenic A. Sica

9. The Renin Angiotensin Axis: Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
Domenic A. Sica, Todd W. B. Gehr, and William H. Frishman

10. The Renin Angiotensin Axis: Direct Renin Inhibition
William H. Frishman and Domenic A. Sica

11. Diuretic Therapy in Cardiovascular Disease
Domenic A. Sica, Todd W. B. Gehr, and William H. Frishman

12. Magnesium, Potassium, and Calcium as Cardiovascular Disease Therapies
Domenic A. Sica and William H. Frishman

13. Inotropic Agents
Thierry H. LeJemtel, Marc Klapholz, and William H. Frishman

14. The Organic Nitrates and Nitroprusside
Jonathan Abrams and William H. Frishman

15. Ranolazine: A Piperazine Derivative
William H. Frishman, James J. Nawarskas, and Joe R. Anderson

16. Nonspecific Antihypertensive Vasodilators
Lawrence R. Krakoff and William H. Frishman

17. Antiarrhythmic Drugs
Peter Zimetbaum, Peter R. Kowey, and Eric L. Michelson

18. Antiplatelet and Other Antithrombotic Drugs
William H. Frishman, Robert G. Lerner, and Harit Desai

19. Thrombolytic Agents
Robert Forman and William H. Frishman

20. Lipid-Lowering Drugs
William H. Frishman and Wilbert S. Aronow

21. New Aspects of Combination Therapy: Focus on Hypertension
Michael A. Weber

22. Pharmacotherapy for Smoking Cessation
William H. Frishman

23. Pharmacotherapy of Obesity
William H. Frishman, Harriette R. Mogul, and Stephen J. Peterson

24. Heart Disease and Treatment of Diabetes Mellitus
Irene A. Weiss, Guy Valiquette, Monica D. Schwarcz, and William H. Frishman

25. Prostacyclins, Endothelin Inhibitors, and Phosphodiesterase-5 Inhibitors in Pulmonary Hypertension
Warren D. Rosenblum and William H. Frishman

26. Selective and Non-selective Dopamine Receptor Agonists
William H. Frishman and Chandrasekar Palaniswamy

27. Natriuretic Peptides: Nesiritide
William H. Frishman and Domenic A. Sica

28. Vasopressin and Vasopressin Receptor Antagonists
William H. Frishman, Marc Klapholz, Gerard Oghlakian, and Jacqueline M. Cook

29. Drug-Eluting Stents
James J. Nawarskas and Mark J. Ricciardi


Part 3: Special Topics

30. Alternative and Complementary Medicine for Preventing and Treating Cardiovascular Disease
William H. Frishman

31. Cardiovascular Drug–Drug Interactions
Angela Cheng-Lai, James J. Nawarskas, and William H. Frishman


Part 4: Appendices

Angela Cheng-Lai and William H. Frishman

1. Pharmacokinetic Properties of Approved Cardiovascular Drugs
2. Therapeutic Use of Available Cardiovascular Drugs

Index

William H. Frishman, MD, MACP; Barbara and William Rosenthal Professor of Medicine, Department of Medicine Chairman, and Professor of Pharmacology, New York Medical College; Director of Medicine, Westchester Medical Center, Valhalla, New York

Domenic A. Sica, MD; Professor of Medicine and Pharmacology, Chairman, Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Virginia Commonwealth University